Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2021-09-02 00:00:00 ET · period of report 2021-09-01 · accession 0001213900-21-046413 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-02 | 2021-09-01 | ORMP | Silberman David | CFO | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| D | 2021-09-02 | 2021-09-01 | ORMP | Silberman David | CFO | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-01 | A | A | 50,000 | $0.00 | 50,000 | D | — | — | (F1) Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F2) The RSUs will vest as follows: 33,333 shall vest in three equal installments over a period of three years upon Issuer's common stock achieving a specified price per share, and 16,667 shall vest in three equal installments over a period of three years upon Issuer's achievement of certain business objectives. |
| 2 | Derivative | Stock Option (right to buy) | 2021-09-01 | A | A | 50,000 | $0.00 | 50,000 | D | $20.19 · — to 2031-09-01 | 50,000 Common Stock | (F3) The Stock Options will vest in four equal installments of 12,500 on each of June 27, 2022, June 27, 2023, June 27, 2024 and June 27, 2025. |